文献速递心脑血管急症消化、代谢与肾脏急症重症综合管理与镇静镇痛

口服抗凝药在无需透析的晚期CKD合并房颤患者中的应用

Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced CKD Not Requiring Dialysis.
PubMed 文献 · JAMA Netw Open · 2026-09-01
一句话结论房颤合并晚期非透析CKD患者,阿哌沙班较不用抗凝降低缺血性卒中但增加大出血,净获益优于华法林。

该回顾性队列研究采用三组目标试验模拟框架,纳入Medicare和Optum数据库2013—2025年房颤合并CKD 4或5期、未透析患者,比较阿哌沙班、华法林与不用口服抗凝药的结局。与不用抗凝相比,阿哌沙班大出血发生率升高(HR 1.32),缺血性卒中发生率降低(HR 0.46),复合终点无差异;华法林大出血(HR 2.44)和复合终点(HR 1.95)均升高。阿哌沙班较华法林大出血(HR 0.55)和缺血性卒中(HR 0.50)风险均更低。提示该人群抗凝的卒中获益与出血风险的权衡,阿哌沙班优于华法林。

要点

  • 房颤合并CKD 4或5期未透析患者,阿哌沙班较不用抗凝:大出血HR 1.32(95%CI 1.11-1.58),缺血性卒中HR 0.46(95%CI 0.32-0.66)。
  • 阿哌沙班较不用抗凝复合终点无差异:HR 1.05(95%CI 0.89-1.22),RD 6.13/1000人年(95%CI -10.61至22.87)。
  • 华法林较不用抗凝:大出血HR 2.44(95%CI 2.06-2.88),缺血性卒中无显著差异(HR 0.87,95%CI 0.61-1.22),复合终点HR 1.95(95%CI 1.69-2.26)。
  • 阿哌沙班较华法林:大出血HR 0.55(95%CI 0.46-0.65),缺血性卒中HR 0.50(95%CI 0.33-0.78),净获益更优。
  • 该研究为回顾性队列的目标试验模拟,非随机对照,结论需前瞻性验证,不能直接作为用药推荐等级。

适用人群与场景

  • 纳入:房颤合并CKD 4或5期、未接受透析、有连续医疗和药房保险覆盖的患者(Medicare按服务收费索赔2013-01-01至2022-12-31;Optum去标识化Clinformatics Data Mart数据库2013-01-01至2025-02-28)。
  • 排除:既往透析患者(原文明确排除),其余排除标准原文未提及。
  • 场景:非急诊/ICU专属,为门诊或住院启动口服抗凝的房颤合并晚期CKD人群。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文比较的是阿哌沙班或华法林启动 vs 不用口服抗凝,未给出具体剂量、给药途径、频次或目标值。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:回顾性队列研究,采用三组目标试验模拟框架,使用倾向评分匹配权重平衡基线特征,估计加权HR和每1000人年率差(RD)。
  • 样本量与人群:阿哌沙班组14 712例(女性7954例[54.1%],平均年龄78.93[SD 7.35]岁),华法林组6335例(女性3148例[49.7%],平均年龄77.47[SD 7.03]岁),不用口服抗凝组21 005例(女性10 797例[51.4%],平均年龄79.59[SD 7.49]岁);均来自Medicare和Optum数据库。
  • 主要终点(阿哌沙班 vs 不用抗凝):大出血住院HR 1.32(95%CI 1.11-1.58),RD 17.16/1000人年(95%CI 2.45-31.87);缺血性卒中HR 0.46(95%CI 0.32-0.66),RD -12.67/1000人年(95%CI -20.65至-4.69);复合终点HR 1.05(95%CI 0.89-1.22),RD 6.13/1000人年(95%CI -10.61至22.87)。
  • 主要终点(华法林 vs 不用抗凝):大出血HR 2.44(95%CI 2.06-2.88);缺血性卒中HR 0.87(95%CI 0.61-1.22,无显著差异);复合终点HR 1.95(95%CI 1.69-2.26)。
  • 主要终点(阿哌沙班 vs 华法林):大出血HR 0.55(95%CI 0.46-0.65);缺血性卒中HR 0.50(95%CI 0.33-0.78)。
  • 关键次要终点与不良事件:原文未提及除大出血、缺血性卒中及复合终点外的其他终点或不良事件。

证据类型、等级与局限

  • 证据类型:回顾性队列研究(目标试验模拟框架),非随机对照试验。
  • 证据等级或推荐强度:原文未给出正式证据分级或推荐强度。
  • 局限:回顾性设计、依赖索赔数据库、可能存在未测量混杂;原文未提及单中心/多中心、样本量局限等具体说明;目标试验模拟结果需前瞻性验证。

对床旁实践的改变

  • 对房颤合并CKD 4或5期未透析患者,该研究提示启动阿哌沙班与降低缺血性卒中相关但增加大出血,临床决策需个体化权衡,不能据此对所有患者常规推荐抗凝。
  • 在需选择口服抗凝药时,该研究提示阿哌沙班较大出血和缺血性卒中风险均低于华法林,可优先考虑阿哌沙班而非华法林(仅限原文比较的该人群)。
  • 常见陷阱:该研究为回顾性队列的目标试验模拟,非RCT,不能将HR解读为因果疗效或直接作为指南推荐等级;原文未提供剂量、监测目标或停药阈值。
  • 适用人群:房颤合并CKD 4或5期、未透析、有连续保险覆盖者;不适用人群:已透析患者(原文排除)。

指南或共识出处

  • 原文未提及指南或共识名称;来源为JAMA Netw Open发表的回顾性队列研究。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: The net benefit of oral anticoagulants (OACs) in patients with atrial fibrillation (AF) and advanced chronic kidney disease (CKD) not receiving dialysis remains uncertain.

OBJECTIVE: To compare the estimated effectiveness and safety of apixaban compared with warfarin and no OAC use among patients with AF and advanced CKD not receiving dialysis.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used a 3-group target trial emulation framework and included patients from Medicare fee-for-service claims (January 1, 2013, to December 31, 2022) and the Optum deidentified Clinformatics Data Mart database (January 1, 2013, to February 28, 2025). Eligible participants had AF, CKD stage 4 or 5, no prior dialysis, and continuous medical and pharmacy coverage. Data analysis was conducted from February 2025 to June 2026.

EXPOSURES: Initiation of apixaban or warfarin vs no oral anticoagulation.

MAIN OUTCOMES AND MEASURES: Primary outcomes were hospitalization for major bleeding, ischemic stroke, and their composite. Propensity score matching weights were used to balance baseline characteristics, and weighted hazard ratios (HRs) and rate differences (RDs) per 1000 person-years (PYs) were estimated.

RESULTS: The study included 14 712 apixaban users (7954 female [54.1%]; mean [SD] age, 78.93 [7.35] years), 6335 warfarin users (3148 female [49.7%]; mean [SD] age, 77.47 [7.03] years), and 21 005 nonusers of OACs (10 797 female [51.4%]; mean [SD] age, 79.59 [7.49] years). Compared with nonusers, apixaban was associated with an increased rate of major bleeding (HR, 1.32 [95% CI, 1.11 to 1.58]; RD, 17.16 [95% CI, 2.45 to 31.87] per 1000 PYs) and a lower rate of ischemic stroke (HR, 0.46 [95% CI, 0.32 to 0.66]; RD, -12.67 [95% CI, -20.65 to -4.69] per 1000 PYs), but there was no association with the composite outcome (HR, 1.05 [95% CI, 0.89 to 1.22]; RD, 6.13 [95% CI, -10.61 to 22.87] per 1000 PYs). Warfarin users had a higher rate of major bleeding (HR, 2.44 [95% CI, 2.06 to 2.88]) and no significant diffrence in the rate of ischemic stroke (HR, 0.87 [95% CI, 0.61 to 1.22]), resulting in a higher rate of the composite outcome compared with nonuse (HR, 1.95 [95% CI, 1.69 to 2.26]). Compared with warfarin, apixaban was associated with lower risk of major bleeding (HR, 0.55 [95% CI, 0.46 to 0.65]) and ischemic stroke (HR, 0.50 [95% CI, 0.33 to 0.78]).

CONCLUSIONS AND RELEVANCE: This study found that among patients with AF and advanced CKD not receiving dialysis, anticoagulation was associated with reduced risk of ischemic stroke, but increased risk of bleeding compared with nonuse, suggesting that the trade-off between ischemic stroke reduction and bleeding risk was more favorable for apixaban than for warfarin.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Chen Q, Singer DE, Fu EL, et al. Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced CKD Not Requiring Dialysis. JAMA Netw Open. 2026. PMID: 42696280. doi:10.1001/jamanetworkopen.2026.32225

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。